Viridian Therapeutics, Inc. (VRDN)

Viridian Therapeutics Stock Forecast

Stock Price Forecast

The 13 analysts that cover Viridian Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $35.46, which forecasts a 150.78% increase in the stock price over the next year. The lowest target is $20 and the highest is $61.

Price Target: $35.46 (+150.78%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$20	$35.46	$32	$61
Change	+41.44%	+150.78%	+126.31%	+331.40%

Analyst Ratings

The average analyst rating for Viridian Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Nov '25	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26
Strong Buy	6	5	6	6	6	6
Buy	4	6	6	6	6	7
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	11	12	13	13	13	14

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Gregory Renza Truist Securities	Truist Securities	Strong Buy Maintains $36 → $33	Strong Buy	Maintains	$36 → $33	+133.38%	Apr 21, 2026
Laura Chico Wedbush	Wedbush	Buy Maintains $37 → $31	Buy	Maintains	$37 → $31	+119.24%	Apr 8, 2026
Richard Law Goldman Sachs	Goldman Sachs	Strong Buy Maintains $36 → $31	Strong Buy	Maintains	$36 → $31	+119.24%	Apr 7, 2026
Lisa Walter RBC Capital	RBC Capital	Buy Maintains $42 → $30	Buy	Maintains	$42 → $30	+112.16%	Apr 7, 2026
Maneka Mirchandaney Evercore ISI Group	Evercore ISI Group	Buy Maintains $45 → $32	Buy	Maintains	$45 → $32	+126.31%	Apr 2, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

80.58M

Increased by 13.73%

from 70.85M

Revenue Next Year

305.40M

Increased by 279.00%

from 80.58M

EPS This Year

-4.09

from -3.32

EPS Next Year

-2.34

from -4.09

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	2.96M	1.77M	314.00K	302.00K	70.85M	80.58M	305.40M
Revenue Growth	182.19%	-40.20%	-82.28%	-3.82%	23,359.93%	13.73%	279.00%
EPS	-6.66	-2.71	-3.91	-3.07	-3.32	-4.09	-2.34
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	18	17

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027	2028	2029	2030	2031	2032	2033
High	217.7M	665.2M
Avg	80.6M	305.4M
Low	18.6M	131.3M

Revenue Growth

Revenue Growth	2026	2027	2028	2029	2030	2031	2032	2033
High	207.2%	725.5%
Avg	13.7%	279.0%
Low	-73.7%	63.0%

EPS Forecast

EPS	2026	2027	2028	2029	2030	2031	2032	2033
High	-2.87	-0.76
Avg	-4.09	-2.34
Low	-5.90	-4.83

EPS Growth

EPS Growth	2026	2027	2028	2029	2030	2031	2032	2033
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.